Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier to treating patients infected with hepatitis C. This case series demonstrates challenges experienced by patients and practitioners in accessing these treatments and highlights several strategies for navigating the treatment preauthorization process.
|Original language||English (US)|
|Number of pages||4|
|Journal||Topics in Antiviral Medicine|
|State||Published - 2017|
- Hepatitis C virus
ASJC Scopus subject areas